Regulatory TEVAR clinical trials  by Garcia-Toca, Manuel & Eskandari, Mark K.
Regulatory TEVAR clinical trials
Manuel Garcia-Toca, MD, and Mark K. Eskandari, MD, Chicago, IllIt has been almost two decades since the first report of
a thoracic endovascular aneurysm repair (TEVAR) by Dake
et al.1 The early devices were custom-made by the opera-
tors themselves, using woven Dacron grafts hand-sewn to
Gianturco Z-stents (Cook Group Europe, Bjaeverskov,
Denmark). A few years after the first published reports
using custom-made devices, a handful of companies started
to produce factory-made endografts. These first generation
commercial devices were superior, particularly in regards to
deployment, and facilitated the increased use of endografts
to treat thoracic aortic pathology.
European collaborators and registries preceded admin-
istrative approval in the United States and contributed
valuable clinical data. In 2005, after 7 years of clinical trials,
the US Food and Drug Administration (FDA) approved
commercial use of the Gore Thoracic Aortic Graft (TAG;
W.L. Gore and Associates, Flagstaff, Ariz). The regulatory
multicenter trials involving these current commercial tho-
racic endografts have provided an enormous amount of
data.
Three commercial devices have completed regulatory
trials and are currently approved for use in theUnited States
by the FDA: Gore TAG, TALENT (Medtronic, Santa
Rosa, Calif), and Zenith TX 2 (William Cook Europe, ApS,
Bjaeverskov, Denmark). One other device, Relay (Bolton
Medical, Inc, Sunrise, Fla) is currently undergoing a phase
II trial in the US. These studies provide the best insight on
the safety and efficacy of TEVAR because they include a rigid
follow-up of a uniformwell-defined population. Additionally,
reporting standards have been defined by the Ad Hoc Com-
mittee of the Society for Vascular Surgery® (SVS)/American
Association for Vascular Surgery (AAVS) in 2002.2 Tech-
nical success is defined as delivery of the device to the
intended location with satisfactory exclusion of the aneu-
rysm and no type I or II endoleaks. Clinical success includes
the outcomes of aneurysm-related deaths, rupture, en-
doleaks, and re-intervention.
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22SGORE TAG ENDOPROSTHESIS
The Gore Excluder thoracic endoprosthesis (W.L.
Gore and Associates) was the first thoracic endograft to
undergo a feasibility trial in the US in 1998, followed by a
pivotal trial in 1999. After the study enrollment was com-
plete, longitudinal wire fractures were detected in the stent
body, leading to voluntary withdrawal of the device from
distribution in May 2001. After structural modifications,
the redesigned device was named TAG endoprosthesis and
underwent a confirmatory trial in late 2003. The FDA
approved commercial use of the Gore TAG endoprosthesis
in March 2005 for the treatment of aneurysms of the
descending thoracic aorta in patients who have appropriate
anatomy including adequate iliac/femoral access, aortic
inner diameter in the range of 23-37 mm, and 2 cm of
non-aneurysmal aorta proximal and distal to the aneurysm.
Feasibility study
The feasibility study was conducted between 1998 and
1999 to establish preliminary device safety data. A total of
28 patients were enrolled at two clinical sites. There was
one death during the 30-day period. No paraplegia or
stroke was noted. At 1-year follow-up, mortality rate was
21%. The 5-year follow-up showed an all-cause mortality
rate of 25%. Endoleaks occurred in 21% of patients, aneu-
rysm sac enlargement in 18%, and stent fractures in 32%. A
re-intervention rate of 7% was reported, and one patient
underwent subsequent open conversion. No aneurysm
rupture, device migration, extrusion, graft erosion, throm-
bosis, or branch vessel occlusion was reported.
Pivotal (phase II) trial
The pivotal trial was conducted to determine the safety
and efficacy of the device for treatment of descending
thoracic aortic aneurysms (DTAA) as compared with open
surgical repair.3 The primary safety hypothesis was that the
percentage of patients with more than one major adverse
event (MAE) through 1-year post-treatment will be lower
in the TAG group as compared with a surgical control
group. The primary efficacy end point was the percentage
of patients free from major device-related events through
the 1-year follow-up for the TAG group. The secondary
hypotheses were that the operative blood loss, intensive
care unit (ICU), hospital stay, and convalescence to normal
activities will be lower in the TAG group versus the surgical
control arm.
Study design. The study was a prospective, nonran-
domized, controlled multicenter trial comparing TEVAR,
using the TAG endoprosthesis, to open repair of thoracic
aortic aneurysms. Between September 1999 and May
2001, 140 study patients and 94 control subjects were
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control group patients, 44 were prospectively acquired
during the study, and 50 were acquired by selecting the
most recent surgical patients in reverse chronological order.
Patients with DTAA of at least twice the diameter of the
normal thoracic aorta and with 2 cm of nonaneurysmal
neck for sealing distal to the left subclavian artery and
proximal to the celiac artery were eligible for endovascular
treatment.
Results. Perioperative (30-day) mortality occurred
significantly less often in the TEVAR group (2.1% vs 11.7%;
P .007), as did respiratory failure (4% vs 20%; P .001),
renal failure (1% vs 13%; P .01), and spinal cord ischemia
(SCI; 3% vs 14%; P  .003). Peripheral vascular complica-
tions were more prominent in the TAG group (14% vs 4%;
P  .015). Lengths of hospital and ICU stay were signifi-
cantly less in the TEVAR cohort. Of the TAG group, 98%
had successful implantation of the endograft, but three
patients had delivery failures due to iliac access difficulties.
In addition, 21 patients (15%) required elective operative
conduit for device delivery. At 3 years, freedom from
aneurysm-related mortality was 97% in those undergoing
TEVAR and 90% in the open surgical controls (P  .024).
All-cause mortality was no different between groups.
Five-year follow-up. The 5-year data from this trial
noted that the benefits of TEVAR appear to be maintained
in the long term.4 While all-cause mortality remains similar
between groups (68% vs 67%; P  .43), aneurysm-related
death continues to be significantly less in those repaired
endoluminally (Fig 1). All aneurysm-related deaths oc-
curred in the first year after treatment. Within the TAG
group, significantly fewer major adverse events were seen at
5 years (57.9% vs 78.7%; P  .001). Endoleak has been
identified at some point in 10.6% of the cohort. However,
only five patients (3.6%) have required aneurysm-related
re-intervention and one open conversion. Indeed, overall
Fig 1. TAG trial freedom from aneurysm-related mortality at 5
years.aneurysm-related secondary procedures were performedless often in the TAG group compared to the open surgical
controls over the 5 years (P  .01). Only one case of
endograft migration of 10 mm or more was noted (0.7%).
For TAG patients, sac size at 60 months decreased in 50%
and increased in 19% compared with the 1-month baseline.
Comparison with the modified low-porosity device at 24
months showed sac increase in 12.9% of original vs 2.9% in
modified grafts (P  .11).
TALENT (VALOR TRIAL)
The “Talent” device is composed of a thin woven
polyester fabric sewn to a self-expanding nitinol wire
frame (See the article by Dr Lyden). In 2005, the Vas-
cular Talent Thoracic Stent Graft System for the Treat-
ment of Thoracic Aortic Aneurysms (VALOR) trial,
using the Talent system, completed enrollment.5 The
results of the study led to FDA approval of the device in
2008 for the treatment of fusiform and saccular aneu-
rysms as well as penetrating thoracic aortic ulcers in
patients having appropriate anatomy, including iliac/
femoral access vessel morphology that is compatible with
vascular access techniques, non-aneurysmal aortic diam-
eter in the range of 18 to 42 mm; and non-aneurysmal
aortic proximal and distal neck lengths 20 mm.
Study design. The study is a prospective, nonrandom-
ized, multicenter trial. It included three arms: pivotal data
group, phase II; high-risk patients; and a registry group.
The pivotal data group results were compared with retro-
spective open surgical data from three centers of excellence
and were used for comparison to open repair. The trial
enrolled 195 patients for endovascular repair, and 189
patients were identified as retrospective open surgical sub-
jects. Standard follow-up interval examinations were pre-
scribed at 1 month, 6 months, 1 year, and annually there-
after. Patients were considered for inclusion if they had a
fusiform thoracic aneurysm 5 cm or 2 times the diam-
eter of the nonaneurysmal aorta, as well as focal saccular
aneurysms or penetrating atherosclerotic ulcers. A notable
exclusion criterion was previous repair of an infrarenal
aortic aneurysm.
Results (pivotal data). Patients received amean num-
ber of 2.7  1.3 stent graft components. Left subclavian
artery revascularization was performed before the initial
stent graft procedure in 5.2% of patients. Iliac conduits
were used in 21.1% of patients. In 33.5% of patients, the
bare spring segment of the most proximally implanted
device was in zones 1 or 2 of the aortic arch. Graft deploy-
ment was successful in 99.5% of the cases. The 30-day
operative mortality was 2.1%, major adverse event (MAE)
41.9%, paraplegia 1.5%, paraperisis 7.2%, and stroke 3.6%.
Endoleak was present in 10%, and 2.6% required secondary
intervention by 6 months. These results are reasonable and
compare favorably with contemporary open repair out-
comes. At 1 year, 159 of the 195 patients enrolled had
completed protocol. All-cause mortality was 16.1%, and
aneurysm-related mortality was 3.1% (Fig 2). Successful
aneurysm treatment without growth or endoleak was
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(10 mm) rate of 3.9% and an endoleak rate of 12.2%.
Stent grafting showed statistically superior perfor-
mance compared with open repair with respect to acute
procedural outcomes (P  .001), 30-day major adverse
events (41% vs 84.4%; P  .001), perioperative mortality
(2% vs 8%; P  .01), and 12-month aneurysm-related
mortality (3.1% vs 11.6%; P  .002) vs open surgery. The
authors concluded that the Talent device is a safe and
effective endovascular option as an alternative to open
surgery.
ZENITH TX2 (STARZ TRIAL)
The Zenith TX2 is a two-piece modular graft made of
woven Dacron fabric sewn to self-expanding stainless steel
Z-stents. (See the article by Dr Lyden). The Study of
Thoracic Aortic Aneurysm Repair with the Zenith TX2
TAA Endovascular Graft (STARZ) trial, using the Cook
Zenith TX2 thoracic endovascular graft, was published in
2008.6 This led to FDA approval of the device the same
year for the treatment of patients with aneurysms or ulcers
of the descending thoracic aorta having vascular morphol-
ogy suitable for endovascular repair, including: adequate
iliac/femoral access compatible with the required introduc-
Fig 2. VALOR trial freedom from aneurysm-related mortality at
5 years.tion systems; non-aneurysmal aortic segments (fixationsites) proximal and distal to the aneurysm or ulcer; with a
length of at least 25 mm; and with a diameter measured
outer wall to outer wall of not greater than 38 mm and no
less than 24 mm.
Study design. This prospective, nonrandomized,
multicenter trial involved 160 patients undergoing TEVAR
with the Zenith TX2 endovascular graft compared with 70
patients anatomically unfit for TEVAR that underwent
open surgical repair. Criteria for endovascular repair was a
DTAA 5 cm, rapid growth 5 mm a year, or ulcers 10
mm in depth and 20 mm in diameter. Type I thoracoab-
dominal aneurysms were eligible if the placement of the
endograft fabric was planned to be above the visceral ves-
sels.
Results. The endovascular graft was successfully im-
planted in 98.8% of patients, an access conduit was used for
device insertion in 9.4%, and left subclavian artery revascu-
larization was performed in 3.2% of cases. The 30-day
mortality (1.9% vs 5.7%) was lower with TEVAR, andmajor
perioperative adverse events were less common (9.4% vs
33%; P .01). Specifically, cardiovascular, pulmonary, and
vascular complications were significantly less in the TEVAR
cohort. Stroke, paraplegia, and paraparesis tended to occur
less often in the TEVAR group (2.5% vs 8.6%; P  .07,
1.3% vs 5.7%; P  .07, and 4.4% vs 0%; P  .10, respec-
tively). Endoleaks were present in 13% at discharge, and
this decreased to 2.6% at 6 months and 3.9% at 1 year. Over
the year after repair, secondary intervention was similarly
necessary in the TEVAR and open groups (4.4% TEVAR vs
5.7% open, P  .74). No statistical difference was seen in
all-cause mortality and aneurysm-relatedmortality between
the groups (Fig 3). Ventilator use, intensive care unit stay,
time to ambulation, bowel function, and hospital discharge
Fig 3. STARZ trial freedom from aneurysm-relatedmortality at 5
years.were all significantly less in those undergoing TEVAR.
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with follow-up) patients.
DISCUSSION
Although definitions, inclusion criteria, and procedures
were not identical, early results are remarkably similar
among the three trials. All patients were good surgical risk
candidates operated on electively with similar demograph-
ics in the trials. Successful completion rates of the endovas-
cular repair were very high in all three studies, and the few
failures were due to access difficulties (Table I). The use of
a conduit varied between 9% and 21% in the trials. The
variable degrees of left subclavian artery revascularization
relate to the protocol used in each; the TAG trial mandated
revascularization when Zone 2 was used for proximal seal-
ing.
The incidence of major adverse events strongly favors
the TEVAR group over open repair in the three trials for
the treatment of appropriate DTAA. The higher endoleak
rates at 30 days (Table II) in the VALOR trial (26%)
compared with the TAG (3.6%) and STARZ (4.8%) trials is
probably related to how they were reported. In the VALOR
trial, all endoleaks within 30 days were included, whereas
only endoleaks at the 30-day follow-up were included in
the other two studies. Endoleak rates decreased at 1-year
follow-up in the VALOR trial to 12.2% (Table III). The
Table I. Trial design and procedural events
Gore TAG VALOR STARZ
Stent graft TAG TALENT TX2
Number of patients 140 195 160
Technical success rate 98% 99.5% 98.8%
1 device 56% 90% 59%
Conduit used 15% 21% 9.4%
Deployment zone 2 20% — 13.2%
Left subclavian artery
revascularization 20% 5.2% 3.2%
Estimated blood loss (mL) 250 371 216
Hospital stay (days) 3.0 6.4 5.0
STARZ, The Study of Thoracic Aortic Aneurysm Repair with the Zenith
TX2 TAA Endovascular Graft; VALOR, Vascular Talent Thoracic Stent
Graft System for the Treatment of Thoracic Aortic Aneurysms.
Table II. Thirty-day results
Gore TAG VALOR STARZ
Mortality 1.5% 2.1% 1.9%
Paraplegia/paraparesis 2.8% (2/2) 8.7% (3/14) 5.6% (2/7)
Stroke 3.5% 3.6% 2.5%
Major adverse event 28% 30% 41.9%
Endoleak 3.6% 25.9% 4.8%
Access complications 14% 9.2% 22%
STARZ, The Study of Thoracic Aortic Aneurysm Repair with the Zenith
TX2 TAA Endovascular Graft; VALOR, Vascular Talent Thoracic Stent
Graft System for the Treatment of Thoracic Aortic Aneurysms.distribution of endoleaks was variable with the VALOR andSTARZ trial reporting a majority of type II endoleaks
versus the TAG study that found more type I and III
endoleaks. These trials showed a marked reduction in para-
plegia/paraparesis in comparison to open procedures.
The only long-term data in regards to TEVAR comes
from the TAG study. In the report of their 5-year results, it
was shown that the difference in aneurysm-related mortal-
ity between open repair and TEVAR persists over this
period of time; however, all-cause mortality showed mini-
mal differences between the open and endovascular treat-
ment.
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